Medicaid Recipients Denied Coverage for Smoking Cessation Pharmacotherapy by Reeves, Kelly N.
Journal of Health Care Law and Policy
Volume 2 | Issue 1 Article 8
Medicaid Recipients Denied Coverage for
Smoking Cessation Pharmacotherapy
Kelly N. Reeves
Follow this and additional works at: http://digitalcommons.law.umaryland.edu/jhclp
Part of the Health Law Commons, Public Health Commons, and the Substance Abuse and
Addiction Commons
This Notes & Comments is brought to you for free and open access by DigitalCommons@UM Carey Law. It has been accepted for inclusion in Journal
of Health Care Law and Policy by an authorized administrator of DigitalCommons@UM Carey Law. For more information, please contact
smccarty@law.umaryland.edu.
Recommended Citation
Kelly N. Reeves, Medicaid Recipients Denied Coverage for Smoking Cessation Pharmacotherapy, 2 J. Health Care L. & Pol'y 102 (1998).
Available at: http://digitalcommons.law.umaryland.edu/jhclp/vol2/iss1/8
MEDICAID RECIPIENTS DENIED COVERAGE FOR
SMOKING CESSATION PHARMACOTHERAPY
KELLY N. REEVES
Forty-six million American adults smoke cigarettes.' Of the
eighty-one percent of adult smokers who try to quit smoking, only
forty percent will abstain for at least one year.2 Clinical studies have
demonstrated that it is extremely difficult to quit smoking without
some form of smoking cessation aid.' Smoking prevalence is highest
among persons with 9 to 11 years of education (37.5%) and among
persons living below poverty level (34.7%).4 Such demographics help
explain the more than 42 percent of Medicaid beneficiaries who are
smokers, compared to the less than 30 percent of adult smokers in the
general population.5 Over the next 25 years, cigarette smoking will
cost the Medicaid program an estimated $39.2 billion dollars in direct
and indirect health care delivery costs.6 While the Food and Drug
Administration (FDA) has approved several prescription and nonpre-
scription drugs for smoking cessation, 7 states are not required to pro-
vide Medicaid coverage for FDA-approved prescription drugs for
1. See Tamar Nordenberg, It's Quittin' Time Smokers Need Not Rely on Willpower Alone,
FDA CONSUMER Nov.-Dec. 1997 (visited June 12, 1998) <http:www.fda.gov/fdac/features/
1997/797 smoke.html> (article on file with the JOURNAL OF HEALTH CARE LAw & POLICY).
This article is a reprint of the original article and contains revisions made in February
1998; see also U.S. Dep't of Health and Human Services, Centers for Disease Control Activi-
ties in the United States, Initiatives by Organizations to Strengthen National Tobacco Con-
trol Activities in the United States; Notice of Availability of Funds for Fiscal Year 1998, 63
Fed. Reg. 20,197, 20,198 (1998) [hereinafter CDC Notice of Availability of Funds].
2. See U.S. DEP'T OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL,
THE HEALTH BENEFITS OF SMOKING CESSATION: A REPORT FROM THE SURGEON GENERAL 600
(1990). About one-third of those that successfully abstain for one year may eventually re-
lapse. See id. at 610.
3. See infra notes 86-90 and accompanying text.
4. See CDC Notice of Availability of Funds, supra note 1, at 20,199; see also Comprehen-
sive Tobacco Control Legislation: Hearing Before the Subcomm. on Health and the Environment of the
House Comm. on Commerce, 105th Cong. 2-4 (1998) (statement of Summit Health Coalition)
(discussing tobacco industry's deliberate targeting of the African American community
and the high smoking-related disease rate in the African American community).
5. See National Center on Addiction and Substance Abuse at Columbia University, The
Cost of Substance Abuse to America's Health Care System (last modified July 1996) <http://
ww.casacolumbia.org/pubs/ju193/heal5.htm>.
6. See id; see also infra notes 101-104 and accompanying text for discussion on direct
and indirect costs of smoking.
7. See infta notes 69-79 and accompanying text for discussion of FDA-approved smok-
ing cessation drugs.
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smoking cessation.8 Currently, only 21 states voluntarily provide Medi-
caid coverage for prescription and nonprescription products indi-
cated for smoking cessation. 9
To reiterate the incredible irony in this policy: smoking cessation
is difficult without the aid of smoking cessation therapy, nearly half of
Medicaid beneficiaries are smokers, FDA-approved smoking cessation
products are available, the Medicaid program would reap cost savings
if there was a reduction in Medicaid smokers, but states do not have to
provide Medicaid coverage for smoking cessation drugs. This paper
will examine the optional Medicaid coverage provision in the Social
Security Act' ° that permits states to exclude Medicaid coverage of
smoking cessation prescription drugs, including its legislative history
and the availability of FDA-approved smoking cessation
pharmacotherapy at the time of its passage in 1990. The paper will
then examine the cost of cigarette smoking to Medicaid and the cost
effectiveness of extending Medicaid coverage to smoking cessation
prescription drugs. The paper will examine current federal govern-
ment smoking cessation initiatives espoused by several federal agen-
cies and programs to illustrate that smoking cessation is clearly a
priority of the national health agenda. Finally, the paper will propose
an amendment to the current law to eliminate states' optional cover-
age of smoking cessation prescription drugs and will examine provi-
8. See Social Security Act § 1927(d)(2)(A)-U), 42 U.S.C. § 1396r-8(d) (2) (A)-(J)
(1971).
9. See Glaxo Zyban Medicaid Coverage Would Be Required Under the Tobacco Bill, "THE PINK
SHEET," F-D-C REPORTS, June 1, 1998, at 10 (citing a July 1997 survey of state policies on
smoking cessation treatment conducted by the National Conference of State Legislatures)
[hereinafter "THE PINK SHEET"].
10. 42 U.S.C. § 1396r-8(d) (2) (A)-(J). Section 1927(d) (2) of the Social Security Act
states:
The following drugs or classes of drugs or their medical uses, may be excluded
from coverage or otherwise restricted:
(A) Agents when used for anorexia, weight loss, or weight gain.
(B) Agents when used to promote fertility.
(C) Agents when used for cosmetic purposes or hair growth.
(D) Agents when used for symptomatic relief of coughs or cold.
(E) Agents when used to promote smoking cessation.
(F) Prescription vitamins and mineral products, except prenatal vitamins and
flouride preparations.
(G) Nonprescription drugs.
(H) Covered outpatient drugs which the manufacture seeks to require as a condi-
tion of sale that associated test or monitoring devices be purchased exclusively
from the manufacturer of it designee.
(I) Barbituates.
(J) Benzodiazepines.
(emphasis added).
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sions of recently-defeated tobacco legislation that would have
accomplished this task, as well as speculate about the likelihood of
Congress considering a similar provision in the near future. By elimi-
nating optional coverage, states will be required to extend Medicaid
coverage to smoking cessation prescription drugs, thereby making
FDA-approved smoking cessation drugs available to Medicaid recipi-
ents, increasing rates of smoking cessation among Medicaid recipi-
ents, and ultimately reducing the cost to Medicaid of providing care
for smokers.
I. MEDICAID'S OPTIONAL EXCLUSION OF COVERAGE FOR
SMOKING CESSATION DRUGS
The Medicaid program was born from the Social Security Act
Amendments of 196511 to ensure that low-income Americans receive
adequate health care.12 The Medicaid program is a federal entitle-
ment program that is administered and partially funded by the states,
but is subject to federal oversight and regulations. 3 The federal gov-
ernment allocates to states a percentage of the Medicaid funding, usu-
ally ranging from 50% to 83% depending on the wealth of the state,
and states contribute the remaining percentage to fund their respec-
tive Medicaid programs.' 4 Attached to the federal government's allo-
cation of Medicaid funding are requirements that states provide
certain services to Medicaid beneficiaries. 15 A state must obtain a
waiver from the Department of Health and Human Services if it in-
tends to stray from the federal requirements. 16 States are not re-
quired by the Social Security Act to provide Medicaid coverage for
prescription drugs. 7 However, if a state does choose to cover pre-
scription drugs, it must cover all prescription drugs and comply with
the federal requirements for prescription drug coverage under Medi-
caid outlined in the Social Security Act.18 Notably, every state and the
11. Social Security Amendments of 1965, Pub. L. No. 89-97, 79 Stat. 286 (codified as
amended in scattered sections of 42 U.S.C.).
12. See S. REP. No. 89-404, at 169 (1965), reprinted in 1965 U.S.C.C.A.N. 1943, 1943; see
also BARY R. FURROW ET AL., HEALTH LAw 864 (3d. ed. 1997).
13. See FuRRow ET AL., supra note 12, at 881.
14. See S. REP. No. 89-404, at 178, reprinted in 1965 U.S.C.C.A.N. 1943, 2024.
15. See id. at 175, reprinted in 1965 U.S.C.C.A.N. 1943, 2021.
16. 42 U.S.C. § 1315 (1998).
17. See S. Re. No. 89-404, at 175, reprinted in 1965 U.S.C.C.A.N. 1943, 2021.
18. See id.; H.R. CONy. REP. No. 101-881 (1990), reprinted in 1990 U.S.C.C.A.N. 2017,
2107.
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District of Columbia provides Medicaid coverage for prescription
drugs.19
A. Section 1927 (d)(2) of the Social Security Act
The statutory provision that allows states to exclude smoking ces-
sation prescription drugs from Medicaid coverage is found in section
1927 of the Social Security Act.2 ° Section 1927 of the Social Security
Act was added by the Omnibus Budget Reconciliation Act of 1990
(OBRA 1990),21 and amended by the Omnibus Budget Reconciliation
Act of 1993 (OBRA 1993).22 With OBRA 1990, Congress focused on
reducing spending in the Medicaid program by: (1) reforming the
purchase of prescription drugs by the states, and (2) by requiring
states to purchase employer group health coverage on behalf of Medi-
caid beneficiaries where cost effective.23 With regard to prescription
drug reform, OBRA 1990 mandated that drug manufacturers would
be limited to charging the Medicaid program the best price given any
bulk purchaser for prescription drugs, subject to a minimum discount
of 10 percent, with savings returned to the state Medicaid program
through a quarterly rebate. 24 A drug manufacturer that refused to
enter a drug rebate agreement with the Secretary of the Department
of Health and Human Services for all the manufacturer's drugs and
with all the states would be denied federal Medicaid matching pay-
ments for the covered outpatient drugs. 25
OBRA 1993 required a drug or biological manufacturer to enter
into a master agreement with the Administrator of the General Serv-
ices Administration (GSA) under which the manufacturer must agree
to enter into Federal Supply Schedule (FSS), Department of Veterans
Affairs (VA) depot, and Department of Defense (DoD) depot pharma-
19. See H.R. CONF. REP. No. 101-964, at 821 (1990), reprinted in 1990 U.S.C.C.A.N. 2526,
2374.
20. Social Security Act § 1927(d), 42 U.S.C. §1396r-8(d)(2)(E) (1998).
21. Omnibus Budget Reconciliation Act of 1990 § 4401, Pub. L. No. 101-508, 104 Stat.
1388 (codified as amended in scattered sections of 42 U.S.C.).
22. Omnibus Budget Recoficiliation Act of 1993 §3602, Pub. L. No. 103-112, 107 Stat.
312 (codified as amended in scattered sections of 42 U.S.C.).
23. See H.R. CONF. REP. No. 101-881, at 4 (1990), reprinted in 1990 U.S.C.C.A.N. 2017,
2107.
24. See 42 U.S.C. § 1396r-8(c); see H.R. REP. No. 101-881, at 96-97, reprinted in 1990
U.S.C.C.A.N. 2017, 2108-09.
25. See 42 U.S.C. § 1396r-8(a). A "covered outpatient drug" includes all prescription
drugs approved by the FDA except those for which Medicaid payments is made as part of
payment for the following services: inpatient hospital, hospice, dental, physician office vis-
its, outpatient hospital emergency room visits, and outpatient surgical procedures. See
§ 1396r-8(k) (2) (a) (i), (k)(3); H.R. REP. No. 101-881, at 97, reprinted in 1990 U.S.C.C.A.N.
2017, 2019.
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ceutical pricing agreements as a condition of selling the drug or bio-
logical to a federal agency,26 and as a condition for receiving payment
for the drug or biological under the Medicaid program, or receiving
payment for the drug or biological directly or indirectly from any en-
tity that receives funds under the Public Health Service Act.27
Section 1927 outlines the Medicaid drug rebate program and sev-
eral prescription drug cost containment methods permissible for
states to employ. 28 Again, states that choose to extend Medicaid cov-
erage to prescription drugs must cover all prescription drugs, subject
to the permissible restrictions outlined in section 1927(d).29 States
may employ prior authorization programs,30 drug formularies,3 1 or
may limit the maximum or minimum quantities per prescription or
on the number of refills, 32 or limit drugs not prescribed for a medi-
cally accepted indication." In addition to these cost containment
measures, a state may exclude a drug, classes of drugs, or their medi-
cal uses from Medicaid coverage if it falls under the list of drugs ex-
empted from coverage in section 1927(d)(2). 4 States are granted
flexibility in determining what medical uses and drugs qualify under
the list of exempted drugs." The statutory list of drugs ranges from
26. Specifically, selling the products to the VA, the DoD, and the Public Health Service.
27. See S. REP. No. 102-401, at 46-47 (1993), repinted in 1993 U.S.C.C.A.N. 4113, 4121.
The term "depot" means a centralized commodity management system operated by the
Department which drugs and biologicals procured for the use of entities of the Depart-
ment are received and delivered. Id. at 43.
28. See 42 U.S.C. § 1396r-8 (1998).
29. See id. § 1396r-8(d).
30. See id. § 1396r-8(d) (5). A prior authorization program requires the approval of a
drug before its dispensing for any medically accepted indication as a condition of coverage
or payment for a covered outpatient drug. See id. § 1396r-8(d) (5). A state's prior authoriza-
tion program must be established in accord with federal requirements. See id. § 1396r-
8(d) (5) (A)-(B).
31. See id. § 1396r-8(d) (4). A drug formulary is a cost containment measure that ex-
cludes payment coverage of certain prescription drugs that do "not have a significant, clini-
cally meaningful therapeutic advantage in terms of safety, effectiveness, or clinical
outcome for treatment" in pertinent populations over other drugs that are included in the
formulary. Id. § 1396r-8(d) (4) (C). The state formulary must be established in accord with
federal requirements. See id. § 1396r-8(d) (4).
32. See id. § 1396r-8(d)(6) ("A State may impose limitations.., on the minimum or
maximum quantities per prescription or on the number of refills, if such limitations are
necessary to discourage waste.").
33. See id. § 1396r-8(d)(1)(B)(i). Medically accepted indication is defined as "any use
for a covered outpatient drug which is approved under the Federal Food, Drug, and Cos-
metic Act [21 U.S.C.A. §301 et.seq.]." Id. §1396r-8(k) (6).
34. Id. § 1396r-8(d)(2)(A)-(J).
35. See Medicaid Program; Payment for Covered Outpatient Drugs Under Drug Rebate
Agreements with Manufacturers, 60 Fed. Reg. 48,442, 48,455 (1995) (to be codified at 42
C.F.R. pts. 441 & 447) (proposed Sept. 19, 1995).
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agents used for cosmetic hair growth to weight loss to prescription
vitamins.36 Among the drugs listed for optional coverage in section
1927(d) (2) are "agents for the promotion of smoking cessation. 37
This is the provision states rely upon to exclude Medicaid coverage for
all prescription smoking cessation pharmacotherapy.38
The Medicaid optional exclusion provision arose from a move-
ment in Congress to reduce the cost of prescription drugs to the
Medicaid program. In developing the cost containment provisions in
OBRA 1990, the House Committee on Energy and Commerce was re-
sponding to the Budget Resolution of 1990, which assumed reduc-
tions of $2.38 billion in Medicaid outlays over the period FY 1991
through 1995.3' The Committee bill sought to achieve these savings
primarily by reforming the purchase of prescription drugs by the
states.4 ° Prior to OBRA 1990, drug manufacturers were extending dis-
counts on prescription drugs to the VA and the DoD, as well as to
large private sector purchasers, including HMOs and hospital group
purchasing organizations.41 The same discounts were not extended to
the Medicaid program.42 Congress determined that the Medicaid
program, which provided health care for the poor, should have the
benefit of the same discounts on drugs that other large public and
private purchasers enjoyed.13 With the passage of OBRA 1990, Con-
gress established the drug rebate mechanism that gave Medicaid the
benefit of the best price for which a manufacturer sells a prescription
drug to any public or private purchaser.44 Prescription drug manufac-
turers were required to enter into drug rebate agreements in order to
qualify for payment as a "covered outpatient drug" under Medicaid.45
In addition to the concern that drug manufacturers were not uni-
formly granting discounts to federal programs, Congress also focused
on reforming prescription drug reimbursement within the Medicaid
program. 6 States were required to implement drug utilization review
committees to oversee prescribing practices and annually report data
on clinical abuse and inappropriate use of prescription drugs to the
36. See id.
37. Id.
38. See id.
39. See H.R. Doc. No. 101-881, at 63 (1990), reprinted in 1990 U.S.C.C.A.N. 2017, 2077.
40. See id.
41. See id.
42. See id.
43. See id.
44. See id.
45. Id. at 97; see also 42 U.S.C. § 1396r-8(a) (1) (1998). See supra note 24, for definition
of "covered outpatient drugs."
46. See 42 U.S.C. § 1396r-8(d).
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Secretary.47 States were also permitted to employ drug formularies,
prior authorization programs, and other permissible restrictions on
the dispensing of prescribed drugs, including the optional exclusion
of coverage for drugs listed in section 1927(d) (2).48
Smoking cessation prescription drugs were included on the statu-
tory list of exempted drugs primarily for two reasons: (1) states al-
ready commonly excluded smoking cessation drugs from Medicaid
coverage, and (2) FDA-approved smoking cessation pharmacotherapy
was not generally available at the time the list was drafted.49 Congress
drafted the list of optional drugs in section 1927(d) (2) based on
drugs that were commonly subject to restriction or exclusion by state
Medicaid programs.50 When states were still individually selecting
which prescription drugs to cover under the Medicaid program prior
to 1990, only one FDA-approved smoking cessation prescription drug
became available, for smoking cessation products were generally re-
garded as ineffective."1 Numerous non-FDA approved smoking cessa-
tion products proliferated the market, such as hypnotherapy audio
tapes and aqua filters; however, such products were often the subject
of Federal Trade Commission sanctions for federal violations of unfair
and deceptive trade practices laws.52 The effectiveness of these prod-
ucts was clearly questionable, prompting most states to exclude them
from Medicaid coverage.53 By including smoking cessation agents on
the list of optionally covered drugs, Congress allowed states to con-
47. See id. § 1396r-8(d) (3).
48. See id. § 1396r-8(d) (4), (d)(5), (d)(6).
49. See infta notes 50-59 and accompanying text.
50. See 136 CONG. REc. H12423-02, H12466 (1990).
51. See Nordenberg, supra note I (describing the prescription drug nicotine gum, a
nicotine replacement therapy, which was approved by FDA for aid in smoking cessation in
1984).
52. See, e.g., PhaseOut of America, Inc.; Prohibited Trade Practices and Affirmative
Corrective Actions, 62 Fed. Reg. 17,831, 17,831 (1997) (describing consent order issued by
the FTC in settlement of alleged violations of federal law prohibiting unfair or deceptive
acts for PhaseOut, a "purported stop smoking device", and requiring firms that distributed
the product to notify identifiable past purchasers of PhaseOut of the FTC's action and
requiring the respondents to have scientific substantiation for claims that PhaseOut
reduces the amount of nicotine, tar and carbon monoxide that smokers receive); Taleigh
Corporation; Proposed Consent Agreement with Analysis to Smoking Cessation Aid, 60
Fed. Reg. 16,148, 16,148 (1995) (describing proposed consent agreement issued by FTC in
settlement of alleged violations of federal law prohibiting unfair or deceptive acts for
Nicotain, a "purported smoking cessation product", and charging proposed respondents
with representing falsely and without reasonable basis that Nicotain enables smokers to
stop smoking quickly and easily and that it works through the same mechanism as a pre-
scription smoking deterrent patch).
53. See generally H.R. Conf. Rep. No. 101-964 (1990), 136 CONG. REc. H12423-02,
H12467 (1990).
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tinue to decide independently whether to spend Medicaid dollars on
potentially ineffective products.
When OBRA 1990 was passed, no nonprescription drugs for
smoking cessation were approved by the FDA and only one FDA-ap-
proved prescription smoking cessation drug was available.54 Prescrip-
tion nicotine gum, a nicotine replacement therapy, was approved by
the FDA for aid in smoking cessation in 1984." 5 In 1993, after eight
years of reviewing various drugs claiming smoking cessation indica-
tions, the FDA issued a final regulation stating that no over-the-
counter drug indicated for smoking cessation was safe and effective.56
The FDA further required any new over-the-counter drug products
containing active ingredients for smoking cessation use to be "new
drugs," which must be approved by the FDA prior to marketing.57 As
will be discussed infra, the number of FDA-approved smoking cessa-
tion prescription and nonprescription drug products available at the
time the statutory list of exempted drugs was drafted was minimal
compared to the number of FDA-approved smoking cessation drugs
currently available.58
54. See Smoking Deterrent Products for Over-the-Counter Use, 58 Fed. Reg. 31,236,
31,240 (1993) (codified at 21 C.F.R. pt. 310); see also Nordenberg, supra note 1.
55. See Nordenberg, supra note 1, at *5.
56. See Smoking Deterrent Products for Over-the-Counter Use, 58 Fed. Reg. at 31,241;
see also Nicotine in Cigarettes and Smokeless Tobacco Is a Drug and These Products Are
Nicotine Delivery Devices Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional
Determination, 61 Fed. Reg. 44,619, 44,788 (1996) ("After extensive premarket review,
FDA concluded that nicotine replacement therapies are efficacious.").
57. See Smoking Deterrent Products for Over-the-Counter Use, 58 Fed. Reg. at 31,241.
This requirement is significant because over-the-counter drugs are not generally subject to
pre-market approval, but rather may just comply with FDA published monographs for spe-
cific drug ingredients. See 21 C.F.R. § 330.10 (1998). The FDA determined that no data
supported safety and effectiveness of any active ingredient for over-the-counter smoking
cessation products and therefore was not adequate to support monograph status for any
ingredient. See Smoking Deterrent Products for Over-the-Counter Use, 58 Fed Reg. at
31,241. A "new drug" is "any drug the composition of which is such that such drug is not
generally recognized, among experts qualified by scientific training and experience to eval-
uate the safety and effectiveness of drugs, as safe and effective for use under the conditions
prescribed, recommended or suggested in the labeling." 21 U.S.C. § 32 1 (p) (1998). FDA-
approval of a drug is significant because it confirms that the drug has been clinically re-
viewed and approved as safe and effective for the drug's indication. See Federal Food,
Drug, and Cosmetic Act of 1938, § 505(d), 21 U.S.C. § 355(d) (1997). The FDA reviews
clinical data from at least two small clinical trials or one large clinical trial of the drug in
humans to determine the safety and effectiveness of a drug. 21 C.F.R. § 330.10.
58. See Nordenberg, supra note 1.
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B. Only Congress is Authorized to Remove a Drug from
Section 192 7(d)(2)
Per section 1927(d) (3) of the Social Security Act, the Secretary of
the Department of Health and Human Services is required to periodi-
cally update the list of drugs, classes of drugs, or their medical uses
found in section 1927(d) (2). 9 To update the list, the Secretary must
determine, based on data collected by surveillance and utilization re-
view programs of state medical assistance programs, that the drug is
subject to clinical abuse or inappropriate use.6" In 1995, the Health
Care Financing Administration (HCFA) issued a rule interpreting sec-
tion 1927(d) (3) which concluded that the Secretary could add drugs
to the statutory list, but did not have the authority to delete drugs from
the list. 61 HCFA determined that the drugs on the list are statutorily
mandated and that the plain language and legislative history of the
statute only granted HCFA the authority to add drugs to the statutory
list.6 2 In its determination, HCFA pointed to the use of the term "up-
date" in the statutory language, which it interpreted to mean only ad-
ding drugs to the list.63 HCFA also relied on the legislative history
revealing that Congress developed the statutory list from drugs that
were commonly subject to exclusion or restriction by state Medicaid
programs.6 4 HCFA determined that both the "tenor of the report"
and the statute suggest "that drugs may be added to the list, but that
the categories already on the list will remain subject to state restric-
tion. '"65 HCFA further noted that if it were to determine that a drug
on the list was not subject to clinical abuse or inappropriate use, it
would have to remove the drug from the list and require all state
Medicaid programs to cover the drug, thus conflicting with the statute
and the legislative history.6 6 HCFA's interpretation of the statute has
not been explicitly rejected by Congress, and as a result, drugs can
only be deleted from the statutory list of optionally covered drugs by
Congress via statutory amendment.
67
59. 42 U.S.C.A. § 1396r-8(d) (3) (West 1998).
60. See id.
61. Medicaid Program; Payment for Covered Outpatient Drugs Under Drug Rebate
Agreements with Manufacturers, 60 Fed. Reg. 48,442, 48,456 (1995) (codified at 42 C.F.R.
pts. 441 & 447) (proposed Sept. 19, 1995).
62. See id.
63. Id.
64. See id.
65. Id.
66. See id.
67. See id.
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II. CONGRESS SHOULD NOT DENY MEDICAID COVERAGE OF
SMOKING CESSATION DRUGS
A. FDA-Approved Smoking Cessation Pharmacotherapy Available in 1998
Circumstances in the smoking cessation prescription drug market
have changed since Congress drafted the statutory list of exempted
drugs in 1990. Several pharmaceutical research companies continued
developing and testing smoking cessation drugs, and were ultimately
successful in demonstrating the safety and efficacy of these products
to the satisfaction of the FDA.6 8 By 1998, FDA had approved three
nonprescription and five prescription smoking cessation drugs.6 9 Of
the prescription drugs now available, four are nicotine replacement
therapy drugs and one is a non-nicotine pill.7 ° Nicotine replacement
therapy delivers small, steady doses of nicotine in the body, normally
delivered by cigarette smoking, to relieve the nicotine withdrawal
symptoms that occur when the smoker quits smoking.71 FDA ap-
proved the nicotine gum, Nicorette®, for sale by prescription in 1984,
and for sale over-the-counter in February 1996.72 The nicotine trans-
dermal patches, Habitrol® and Prostep®, were approved for sale by
prescription in 1992, and approved for sale over-the-counter in July
1996.7' Nicotine nasal spray and a nicotine inhaler were approved for
sale by prescription in March 1996 and May 1997 respectively.74 Few
side effects have been reported with the nicotine replacement gum or
patches, which account for more than 90 percent of the nicotine re-
placement market. 75 The non-nicotine pill, Zyban®, was originally
approved as an anti-depressant prescription drug and marketed by
68. See supra note 56 for FDA requirements for showing of safety and effectiveness.
69. See Nordenberg, supra note 1.
70. See id.
71. See id. ("As with other addictive drugs, people can experience withdrawal when they
get less nicotine than they are used to ... [S]ymptoms can include irritability, frustration,
anger, anxiety, difficulty concentrating, restlessness, and craving for tobacco.").
72. See id. Nicorette® is manufactured by SmithKline Beecham. See Medicaid Coverage
of Smoking Cessation Rx, OTC Products Would Be Required Under Senate floor Version of McCain
Tobacco Bill, HEALTH NEws DAiLY, F-D-C-REPoRTS, May 27, 1998, at 1.
73. See Nordenberg, supra note 1. Habitrol® is manufactured by Novartis and Pros-
tep® is manufactured by Lederle. See Medicaid Coverage of Smoking Cessation Rx, supra note
72, at 1. The over-the-counter smoking cessation transdermal patches are marketed under
the names Nicotrol CQ® and Nicoderm®, manufactured by McNeil Consumer Products
and SmikthKline Beecham. See id.
74. See Nordenberg, supra note 1. These products are marketed under the names
Nicotrol Inhaler® and Nicotrol Nasal Spray® and are manufactured by McNeil Consumer
Products. See Sandra G. Boodman, Feeding the Nicotine Habit: Finding Safer Substitutes for
Cigarettes, WASH. PosT, June 30, 1998 § 2 (Health), at 10.
75. See Boodman, supra note 74, at 10. While nicotine in replacement products is gen-
erally a safe substance and smokers generally consume less nicotine, it still has some side
1998]
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Glaxo Welcome as Wellbutrin®.76 Zyban® works by suppressing
dopamine levels in the brain that are associated with nicotine addic-
tion, reducing nicotine withdrawal symptoms and the urge to
smoke.77 The FDA approved the smoking cessation indication for
Zyban® in May 1997.78 Drug companies continue to develop new
treatments - at least a half a dozen products are currently being
tested, including a nicotine lozenge, a reusable lollipop, and a triple-
strength patch.79
Smoking cessation prescription drugs are not prohibitively costly,
particularly when compared to other prescription drugs currently cov-
ered by Medicaid.8" Nicotine replacement therapy varies from $160
to $300 for treatment and is generally prescribed for six to twelve
weeks, depending on the product and the patient."' The non-nico-
tine pill costs $2.56 per day of treatment, and is generally prescribed
for seven to twelve weeks.82 The daily cost of using the nicotine re-
placement gum or patch is roughly equivalent to a cigarette habit of a
pack and a half per day.8" But the cost of smoking cessation products
may be onerous to low income smokers who buy cigarettes by the pack
and are accustomed to only scraping together a few dollars to buy a
pack rather than paying $30 to $50 at one time for smoking cessation
pharmacotherapy.84 Unfortunately, the cost of paying for smoking
effects. Nicotine raises the heart rate, and nicotine's effect on fetal development, nursing
infants, and individuals with certain heart problems is unknown. See id.
76. See id; Nordenberg, supra note 1; "THE PINK SHEET," supra note 9, at 10.
77. See Richard D. Hurt et al., A Comparison of Sustained-Release Bupropion and Placebo for
Smoking Cessation, 337 NEW ENG.J. MED. 1195, 1201 (1997); see also Nordenberg, supra note
1, at *3. Dopamine is a neurotransmitter in the central nervous system. MILLER-KEANE
ENCYCLOPEDIA & DICTIONARY OF MEDICINE, NuRSING & ALLIED HEALTH 443 (5th ed. 1992).
78. See Nordenberg, supra note 1. Common side effects of Zyban® are dry mouth,
difficulty sleeping, shakiness, and skin rash; individuals with pre-existing seizure condi-
tions, such as epilepsy, or with an eating disorder, such as anorexia or bulemia, should
avoid using the drug. See Hurt et al., supra note 77, at 1199, 1201. One positive side effect
of Zyban® is the significantly smaller weight gain resulting from smoking cessation with
the use of the drug. See id. at 1200-01.
79. See Boodman, supra note 74, at 10.
80. For example, Viagra®, which was recently approved by the FDA for treatment of
male impotence, retails for $10 per pill. See Kaiser Vetoes Viagra Coverage: HMO Says Popular
Impotence Treatment Is Too Costly (visited June 19, 1998) <http://www.cbs2.com/news/sto-
ries/news-980619-091208.html >. See infra text accompanying notes 80-84 for discussion of
retail price of smoking cessation drugs.
81. See Kicking the Habit. . . With Help, (visited July 8, 1998) <http://
www.homearts.com/gh/health/0197hcbl .htm>.
82. See New Aid to Smoking Cessation Treatment Available to Help Smokers Declare Indepen-
dence from Cigarettes, (last modified Aug. 18, 1997) <http://familymedicine.tqn.com/li-
brary/weekly/aa081897.htm>, reprinted from PR Newswire, July 1, 1997.
83. See Boodman, supra note 74, at 10.
84. See id.
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cessation treatment, however nominal, will likely preclude Medicaid
recipients from using smoking cessation aids.8 5
Nicotine addiction is almost impossible to overcome without in-
tervention assistance.8 6 Nearly half of smokers who quit "cold turkey"
relapse within the first 48 hours. 87 For many smokers, nicotine is both
physically and mentally addictive.8 8 Smoking is a powerful addiction
that warrants appropriate medical treatment.8 9 Dr. Michael Fiore, di-
rector of the Center for Tobacco Research and Intervention at the
University of Wisconsin Medical School explains: "As a rule, people
who smoke more than 10 cigarettes a day and want to quit should use
an FDA-approved smoking cessation product."9 Studies have shown
that the most effective smoking cessation treatment is pharmacother-
apy combined with smoking cessation counseling.9 1 While adding
pharmacotherapy increases the cost of each intervention, it also sub-
stantially increases their marginal effectiveness.9 2 Smokers who use
the nicotine gum or transdermal patch increase their chances of quit-
ting from about 5 percent to between 10 and 20 percent, depending
on motivation and other factors.9" Smokers who are highly motivated
and use nicotine replacement therapy products in conjunction with
supportive counseling increase their chance of quitting to 30 per-
cent.9 4 While using prescription drugs can ease the symptoms result-
ing from the physical addiction to nicotine, group or individual
counseling as well as encouragement from family members and
friends are critical in addressing the mental addiction to nicotine. 9
5
State Medicaid programs should provide beneficiaries with access to
85. See id. Last year, nicotine replacement products accounted for $350 million in sales
compared to annual U.S. cigarette sales of at least $25 billion. See id. (citing IMS Health, a
health care information company that compiles pharmaceutical company sales data).
86. SeeJerry Cromwell, et al., Cost-effectiveness of the Clinical Practice Recommendations in
the AHCPR Guideline for Smoking Cessation, 278 JAMA 1759, 1763 (1997); see also Boodman,
supra note 74, at 10.
87. See Boodman, supra note 74, at 10 (citingJohn R. Hughes, an addiction expert who
is a professor of psychiatry, University of Vermont School of Medicine).
88. See Nordenberg, supra note 1.
89. See id.
90. Id.
91. See Cromwell et al., supra note 86, at 1763 (assuming three quarters of United States
smokers tried to quit within a year using transdermal nicotine).
92. See id. at 1764.
93. See Boodman, supra note 74, at 10.
94. See id.
95. See Nordenberg, supra note 1. (statement of Celia Jaffe Wichell, M.D., psychiatrist
and FDA's medical team leader for addiction drug products) ("If someone is serious about
quitting, the drugs alone won't do it... [T]hey must have some kind of support, whether
it's from a formal stop-smoking program or at least informal support from their friends
and family.").
1998]
JOURNAL OF HEALTH CARE LAW & POLICY
smoking cessation prescription drugs and smoking cessation counsel-
ing to most effectively facilitate smoking cessation and yield the high-
est quit rates.
B. Providing Smoking Cessation to Medicaid Recipients Is Cost Effective
Smokers incur demonstrably higher health care costs than non-
smokers. Tobacco use is linked to 30% of all cancers, 25% of all heart
attacks and strokes, and more than 90% of all chronic obstructive pul-
monary disorders (COPD).96 The Centers for Disease Control and
Prevention declared tobacco use the chief avoidable cause of prema-
ture death in the United States; it results in nearly 420,000 deaths an-
nually.97 In addition, smokers can impact the health of nonsmokers,
family members, and others who breathe secondhand smoke.9" Pas-
sive cigarette smoke causes approximately half of all asthma, chronic
bronchitis, and frequent wheezing in children aged two months to
two years. 99 Smokers experience an average of 6% more physician
office visits and spend an average of 27% more days in the hospital
annually than nonsmokers.' 00
The direct and indirect costs to society of cigarette smoking are
dramatic: Americans spend an estimated $50 billion annually on di-
rect medical care for smoking-related illnesses, about 10% of the total
health bill in America, and spend another $47 billion annually on lost
productivity and forfeited earnings due to smoking-related disabil-
ity.' O Tobacco-related illness accounts for $8.2 billion of the $18.2
96. See Michael C. Fiore, The Cost Effectiveness of the AHCPR Smoking Cessation
Clinical Practice Guideline, AMA/American Public Health Ass'n (Dec. 1997) (media brief-
ing) (briefing on file with the Journal of Health Care Law & Policy); W. Martin Davis, To-
bacco/Nicotine Dependence and Cessation Therapies, DRUG Topics, Sept. 7, 1998, at 62-63
(describing the link between smoking and lung cancer and coronary artery disease).
97. See Cigarette Smoking-Attributable Mortality and Years of Potential Life Lost- United States,
1990, 42 MORBIDITY AND MORTALIITYWKLY. REP. 645, 645-49 (1993). In fact, approximately
one out of every five deaths in the U.S. is attributed to smoking. See id. Tobacco use kills
more people each year than AIDS, car accidents, alcohol, homicides, illegal drugs, sui-
cides, and fires, combined. See INSTITUTE OF MEDICINE, GROWING Up TOBACCO FREE:
PREVENTING NICOTINE ADDICTION IN CHILDREN AND YOUTHS 3 (Barbara S. Lynch & Richard
J. Bonnie eds., 1994).
98. See Nordenberg, supra note 1.
99. See Smoking Cessation: Hearings Before the Senate Labor and Human Resources Committee,
105th Cong. (1997) (statement of John M. Eisenberg, M.D., Administrator, Agency for
Health Care Policy and Research) (citing study by Peter Gergen of the Agency for Health
Care Policy and Research) available in www.senate.gov/labor/hear/2108hrg/eisenb.htm.
100. See Cromwell et al., supra note 86, at 1763.
101. See Agency for Health Care Policy and Research, U.S. Dep't of Health and Human
Services, Smoking Cessation: A Systems Approach (visited June 9, 1998) <http://
www.ahcpr.gov/clinic/smokesys.htm> ; see alsoJon D. Hanson & Kyle D. Logue, The Cost of
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billion in substance abuse-related costs to Medicaid.' These costs
reflect only inpatient hospital costs to Medicaid, and not outpatient
hospital costs, emergency room services, payments to physicians, or
costs to Medicare or other public programs.' °3 The total cost to Medi-
caid from smoking is estimated to be $322 billion over the next 25
years.' 0 4
Smoking cessation improves the health of smokers, thereby re-
ducing their need for treatment for smoking-related illness. When a
smoker quits smoking, her risk of heart disease and lung cancer de-
crease steadily. 10 5 In fact, three years after quitting, the risk of dying
from a heart attack is approximately the same as a nonsmoker.1 0 6 Ten
years after quitting, the risk of lung cancer declines about 30% to 50%
of a continuing smoker's risk.'0 7 The 1990 Surgeon General's report,
The Health Benefits of Smoking Cessation, concluded smoking cessation
has major health benefits for men and women of all ages, and these
benefits apply to persons with and without smoking-related disease.10 8
The health benefits of smoking cessation are somewhat difficult to
assess because the benefits are delayed many years, occurring through
decreased morbidity and mortality across a wide range of illnesses.' 0 9
However, smoking cessation clearly leads to lower incidence of dis-
ease, which in turn leads to lower incidence of utilization of health
care services." 0 Lower utilization of health care services leads to de-
creased costs of providing health care to Medicaid smokers."' Smok-
ing cessation intervention such as pharmacotherapy is an inexpensive
Cigarettes: The Economic Case forEx Post Incentive-Based Regulation, 107 YALE L.J. 1163, 1229-31
(1998) (discussing cost effectiveness of smoking cessation).
102. See National Center on Addiction and Substance Abuse at Columbia University,
supra note 5. Drug-related conditions account for $5.6 billion and alcohol-related diseases
account for $4.4 billion in substance abuse-related costs to Medicaid. See id.
103. See id.
104. See id. Since 1980, Medicaid costs have grown at an annual average rate of 13%, as
opposed to only a 4.4% annual increase in the Consumer Price Index. See id.
105. See Nordenberg, supra note 1.
106. See id. (quoting the American Heart Ass'n).
107. See id. (quoting the American Heart Ass'n).
108. See Smoking Deterrent Drug Products for Over-the-Counter Human Use, 58 Fed.
Reg. 31,236, 31,238 (1993) (codified at 21 C.F.R. pt. 310).
109. See Cromwell et al., supra note 86, at 1759-60.
110. See id. at 1759; see also Steven R. Cummings et al., The Cost-effectiveness of Counseling
Smokers to Quit, 261 JAMA 75, 75 (1989); Kevin Fiscella & Peter Franks, Cost-effectiveness of the
Transdermal Nicotine Patch as an Adjunct to Physicians'Smoking Cessation Counseling, 275 JAMA
1247, 1247 (1996); Gerry Oster et al., Cost-effectiveness of Nicotine Gum as an Adjunct to Physi-
cian's Advice Against Cigarette Smoking, 256JAMA 1315, 1315 (1986).
111. See National Center on Addiction and Substance Abuse at Columbia University,
supra note 5.
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way to reduce Medicaid costs, particularly when compared to the cost
of providing health care for the lifetime of a smoker.
12
In a study examining the cost effectiveness of smoking cessation
intervention, researchers assessed the cost and success rates of a smok-
ing cessation program that combined counseling with pharmacother-
apy. t 3 The study determined that providing patients with smoking
cessation counseling without pharmacotherapy was not as successful
and therefore not as cost effective as providing patients with a smok-
ing cessation program that combined counseling with pharmacother-
apy.1 "4 The study estimated the cost of implementing such a program
nationally was $3,779 per quitter, for which society could expect to
gain 1.7 million new quitters.1 15 The overall cost of providing smok-
ing cessation treatment per year of life saved is estimated to be
$2,587.116 The more intensive the intervention, the lower the cost per
year of life saved, which suggests that greater spending on interven-
tion yields more net benefit. 117 The study also found that smoking
cessation programs that involved more intensive counseling and the
nicotine patch had the highest rate of success.11 Smoking cessation
intervention is also extremely cost effective when compared to other
prevention interventions. 1 ' For example, mammography screening
costs about $26,000 per year of life saved and hypertension screening
costs almost $55,500 per year of life saved.12 ° Other than immuniza-
tion, smoking cessation is the most cost effective prevention interven-
tion for adults; no other intervention provides the same return on
investment as smoking cessation treatment. 21
As further testament to the cost effectiveness of smoking cessa-
tion intervention, 75 percent of private sector managed care covers
112. See Cromwell et al., supra note 86, at 1763-64; see also supra notes 99-104 and accom-
panying text for direct and indirect costs of smoking and cost savings from smoking cessa-
tion. In addition to direct health benefits for smokers, increasing the rate of smoking
cessation for adults may aid in reducing the number of teenagers who start smoking. See
Mike Males, The Influence of Parental Smoking on Youth Smoking. Is the Recent Downplaying
Justified?, 65J. OF SCHOOL HEALTH 228, 230 (1995). Studies demonstrate that the children
of parents who smoke are also more likely to smoke and be resistant to smoking prevention
education messages. See id.
113. See Cromwell et al., supra note 86, at 1766.
114. See id. at 1764-65.
115. See id.
116. See id.
117. See id. at 1759.
118. See id. at 1765-66.
119. See id.
120. See id.; see also T. Tengs, et al., Five Hundred Life-Saving Cost Interventions and Their
Cost-effectiveness, 15 RjsK ANALysis 369, app. at 378, 383 (1995).
121. See Cromwell et al., supra note 86, at 1766.
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smoking cessation intervention and treatments. 122 That the majority
of private sector managed care organizations provide coverage for
smoking cessation prescription drugs implies managed care recog-
nizes the cost effectiveness of encouraging their members to quit
smoking.123 The cost of providing effective smoking cessation treat-
ment is minimal when compared with the cost of treating a heart at-
tack, stroke, or cancer which result from smoking.1 24 Due to the
potential for cost savings, smoking cessation has been cited as the
"gold standard" by which all other prevention treatments can be
compared.1 2
5
C. Federal Government Smoking Cessation Initiatives in
Agencies and Programs
Smoking cessation is clearly a national priority, as evidenced by
the federal government's sponsorship of several smoking cessation ini-
tiatives through federal agencies and programs. The federal govern-
ment encourages smoking cessation through the Agency for Health
Care Policy and Research (AHCPR), the Centers for Disease Control
and Prevention (CDC) and Healthy People 2000, and through other
health programs for military personnel. 26 All military services are re-
quired to establish a health promotion program, a component of
which must address smoking cessation and prevention.1 27 Military
smoking cessation and prevention programs are required to provide
smokers with encouragement and professional assistance in quitting,
and require military health care providers, as part of routine physical
and dental examinations, to advise smokers of the risk of tobacco use
and where to obtain help to quit smoking. 128
Healthy People 2000 is a national health activity sponsored by the
CDC to reduce morbidity and mortality, and improve the quality of
122. See Research Funding: Managed Care Plans Should Enhance Identification of Individual
Smokers, "THE BLUE SHEET," F-D-C REPORTS, May 20, 1998 (citing a 1997-98 Robert Wood
Johnson Foundation survey of managed care entities).
123. See id. Managed care organizations survive by focusing on providing preventive
services to their members and improving cost savings in health care delivery. See FuRxow
ET.AL., supra note 12, at 284.
124. See Cromwell et al., supra note 86, at 1766 (referring to author's analysis which
indicates very low cost-effectiveness ratios for smoking cessation intervention compared to
other medical interventions).
125. David M. Eddy, David Eddy Ranks the Tests, 17 HARv. HEALTH LETTER 10, 11 (July
1992).
126. See infra notes 139-145 and accompanying text.
127. See 32 C.F.R. § 85.6(a)-(d) (1998).
128. See id. at § 85.6(d) (1) (i)-(vii).
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life of all Americans.129 One of the Healthy People 2000 goals is to
reduce cigarette smoking in the United States to no more than 15% of
people aged 18 years or over by the year 2000.130 The CDC achieves
its smoking cessation goals by annually offering grants to national
organizations that provide smoking cessation programs to minority
populations and youth.1 3' The CDC endorses smoking cessation pro-
grams that combine nicotine replacement therapy, social support, and
skills training/problem solving techniques for achieving and main-
taining abstinence.' 3 2 The CDC has awarded tobacco control cooper-
ative agreements to state health agencies to develop infrastructure
and strengthen capacity to implement tobacco control programs, and
to collaborate with other national organizations and health agencies
in the implementation of local and state tobacco control programs.1
33
The Agency for Health Care Policy and Research (AHCPR) is-
sued smoking cessation guidelines for clinicians in 1996.134 The
AHCPR guidelines recommend prevention activities primary care phy-
sicians should undertake when they encounter patients who smoke.'
3 5
In the smoking cessation guidelines, AHCPR recommends that clini-
cians offer smoking cessation treatments to every person who smokes
at every office visit, and further recommends that smoking cessation
treatments, both pharmacotherapy and counseling, should be pro-
vided as paid services of health insurance.13 6 The AHCPR smoking
cessation guidelines were distributed to 200,000 primary care physi-
cians by the American Medical Association (AMA), and were en-
dorsed by the AMA and the American Academy of Family
Physicians.1 3 ' AHCPR notes that smoking cessation pharmacotherapy
and counseling are not consistently provided as paid services for sub-
scribers of health insurance packages.1 3' AHCPR further advises that
smoking cessation intervention is as cost effective as other covered
preventive services, such as treatment of mild or moderate hyperten-
129. See CDC Notice of Availability of Funds, 63 Fed. Reg. 20,197, 20,197 (1998).
130. See id. at 20,198.
131. See id. at 20,197; see also Initiatives by Organization to Strengthen National Tobacco
Control Activities in the United States, 62 Fed. Reg. 36,550, 36,550 (1997).
132. See CDC Notice of Availability of Funds, 63 Fed. Reg. at 20,199.
133. See id.
134. See Smoking Cessation: A Systems Approach, supra note 101.
135. See id.
136. See id.
137. See AHCPR Encourages Physicians To Help Smokers Kick the Habit, MANAGED CARE
MAGAZINE (June 1996) (visited June 30, 1998) <http://www.managedcaremag.com
/archiveMC/9606/MC9606.guidelines.shtml.>.
138. See Smoking Cessation: A Systems Approach, supra note 101.
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sion or high cholesterol, and therefore clinicians should be reim-
bursed for smoking cessation treatment.'39
Clearly, the optional exclusion of smoking cessation pharma-
cotherapy from Medicaid coverage does not comport with the federal
government's investment in smoking cessation as illustrated by the
military guidelines on smoking cessation and prevention programs,
the Healthy People 2000 goals, CDC tobacco control funding initia-
tives, or AHCPR smoking cessation guidelines and recommendations.
Medicaid coverage of smoking cessation prescription drugs should
not be the exception to this national priority of smoking cessation.
III. PROPOSED LEGISLATIVE CHANGE TO LAW GOVERNING MEDICAID
OPTIONAL DRUG EXCLUSIONS
As discussed previously, HCFA has refuted its authority to delete
drugs from the statutory list of exemptions in section 1972(d) (2), and
therefore drugs can only be removed if Congress statutorily amends
the list. 4 ' As long as smoking cessation prescription drugs appear on
the list of exemptions, states will have the option of providing Medi-
caid coverage regardless of the evidence of cost effectiveness of smok-
ing cessation intervention. Congress should therefore repeal line (E),
"Agents which promote smoking cessation", of section 1927(d) (2) of
the Social Security Act to ensure that states extend Medicaid coverage
for smoking cessation prescription drugs. By this legislative action,
states would be required to treat smoking cessation drugs the same as
all other prescription drugs under the law governing Medicaid.
14 1
States would retain the ability to subject smoking cessation prescrip-
tion drugs to state drug formularies, prior authorization programs,
and other permissible limitations on prescription drugs employed by
state Medicaid programs. 142 However, states would not be permitted
to dismiss from coverage the entire class of smoking cessation drugs,
as the law currently permits. Medicaid beneficiaries would at last have
access to some form of smoking cessation treatment.
Recent Senate legislation on the tobacco litigation settlement
sponsored by Senator John McCain (R-Ariz.) contained an amend-
ment that would have eliminated smoking cessation drugs from the
statutory list of exempted drugs by repealing line (E) of section
139. See id.
140. See supra notes 59-67 and accompanying text.
141. See supra notes 15-19 and accompanying text.
142. See supra notes 28-33 and accompanying text.
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1927(d) (2).'43 The McCain Bill met its demise on the Senate floor on
June 17, 1998, and the manager's amendment to section 1927(d) (2)
died with it.'44 Several bills pertaining to tobacco control are still ac-
tive, but none as comprehensive or with the same level of support
maintained by the McCain Bill.145 The remaining tobacco-related
bills are narrowly focused on juveniles, minorities, or veterans, and are
therefore not a likely vehicle for an unrelated provision repealing a
section in the Medicaid law.146 When the McCain Bill was still active,
the provision removing smoking cessation drugs from the list of ex-
emptions received support from the American Medical Association
(AMA) and from pharmaceutical companies that market smoking ces-
sation products.' 47 The AMA announced its support in the media for
coverage of FDA-approved pharmacotherapy for smoking cessation by
Medicaid and by private insurers.148
It is unlikely that Congress will soon consider this issue again.
The opinion polls show that voters are not particularly interested in
anti-tobacco legislation, diminishing the likelihood that any anti-to-
bacco legislation will be considered by the full Congress this year. 149
Because the nature of repealing one line in the Social Security Act is
143. Universal Tobacco Settlement Bill, S. 1415, 105th Cong. § 261 (1998); see also Medi-
caid Coverage of Smoking Cessation Rx, OTC Products Would Be Required Under Senate Floor Ver-
sion of McCain Tobacco Bill, HEALTH NEWS DAILY, F-D-C REPORTS, May 27, 1998. The
language in the McCain bill would also have included coverage for smoking cessation OTC
treatments as well as prescription drug treatments. See id. Many states balk at the notion of
covering OTC therapies for smoking cessation because of the fear of expanding coverage
to all OTC drugs. See Smoking Cessation Therapies Approved by FDA Should Be Covered by Medi-
caid and Private Insurers, HEALTH NEws DAILY, F-D-C REPORTS, June 16, 1998. This legislative
proposal discussed herein is limited to prescription drugs for smoking cessation for that
reason.
144. See Bill Summary and Status for the 105th Congress, S.1415, (visited July 6, 1998),
<http://thomas.loc.gov/cgi-bin/bdquery/d105 query.html>; 144 CONG. Rc. S72471-02
(1998); Tobacco Bill Dies in Senate After a Fierce Four-Week Floor Fight; Settlement Between Big
Tobacco and States is Stalled, ST. Louis POST DISPATCH, June 18, 1998, at Al.
145. See, e.g., Youth Protection from Addition Act of 1997, H.R. 762, 105th Cong.
(1997); Bipartisan No Tobacco for Kids Act of 1998, H.R. 3868, 105th Cong. (1998);
Healthy Kids Act, S. 1638, 105th Cong. (1998); Minority Community Tobacco Reduction
Act, H.R. 4189, 105th Cong. (1998); Veterans Tobacco Trust Fund Act of 1998, H.R. 4188,
105th Cong. (1998); Veterans Benefit Restoration Act of 1998, H.R. 4220, 105th Cong.
(1998); H.R. 4159, 105th Cong. (1998) (proposing amendment to Public Health Service
Act to waive sanctions against states that enact driver's licence-related sanctions for minors
who purchase or possess tobacco products for personal consumption).
146. See supra note 145.
147. See Smoking Cessation Therapies Approved by FDA Should Be Covered by Medicaid and
Private Insurers, supra note 143; "THE PINK SHEET," supra note 9, at 10.
148. See Smoking Cessation Therapies Approved by FDA Should Be Covered by Medicaid and
Private Insurers, supra note 143.
149. See GOP Leaders Put Smoking Bill on Back Burner, Officials Say Republicans Believe The
Teen Smoking Issue Isn't A Concern Among Voters, GREENSBORO NEWS & REc., Aug. 1, 1998, at
[VOL. 2:102
DENIED COVERAGE
comparatively minor legislative action, Congress is not likely to inde-
pendently move to pass a bill focused solely on this issue. Rather, this
legislative action is best suited for a small provision in a larger bill
related to the issue, and therefore will require a vehicle to be consid-
ered again by Congress.
IV. CONCLUSION
Repealing the provision permitting states to optionally exclude
Medicaid coverage for smoking cessation pharmacotherapy is a simple
action Congress could undertake to help Medicaid recipients who
want to quit smoking. Five smoking cessation prescription drug prod-
ucts approved by the FDA are currently available, and the safety and
efficacy of these products has been demonstrated. However, under
the current law, Medicaid recipients are at the mercy of their respec-
tive states for access to FDA-approved smoking cessation drugs. Smok-
ing cessation pharmacotherapy can vastly improve the health and
quality of life of Medicaid smokers, while simultaneously reducing the
overall cost to the Medicaid program of providing health care to treat
tobacco-related illness. By repealing a single line from section
1927(d) (2) of the Social Security Act, Congress can have a profound
positive effect on the lives of millions of Medicaid smokers.
A4; Lawrence Kudlow, With the Help of a Hidden Hand, WASH. TIMES, July 19, 1998, at B3;
Helen Dewar, House Approves Campaign Finance Limits, WASH. POST., Aug. 7, 1998, at Al.
1998]
